Small-Cap Biotech Stocks to Watch (AGTC,THLD,CRIS,OPHT)

I found some very interesting information when conducting research on small-cap biotech stocks. Most disturbing: Well-respected analysts recommended an abundance of small-cap biotech stocks that have since been annihilated. My job is to give readers ideas where they can start research to not only potentially make money, but to stay away from dangerous names. It’s not going to do any […]

See Ya Later Techies: Atlas Venture Goes It Alone, Scoops Up $280M for Biotech

Atlas Venture went through a corporate divorce last fall, as its tech partners and biotech partners went their separate ways. Now the biotech team has moved on, and re-loaded with twice the money they’ve had in the past.The Cambridge, Mass.-based firm, founded back in 1980, is announcing today it has closed on a new $280 million fund, its tenth, to […]

Biotech Stock Roundup: Biogen Soars on Alzheimer's Data, Gilead …

It’s been an eventful week on the pipeline front with companies like Biogen (BIIB – Analyst Report), Prothena (PRTA – Snapshot Report) and Vertex (VRTX – Analyst Report) coming out with data. Meanwhile, Gilead (GILD – Analyst Report) was back in the news once again due to its hepatitis C virus (HCV) franchise.Recap of the Week’s Most Important Stories1. Hopes […]

3 Small-Cap Biotech Stocks That Could Be Top Stocks in 2015

Source: Flickr user .The pop-and-drop nature of the biotech industry makes owning stocks in the sector particularly dicey. But for investors willing to take on the risk of failure, a number of intriguing small-cap biotech companies are working on important new therapies that could make a big impact on patients’ lives and investors’ wallets. Here are three of thesecompanies.No. […]

Why Pfizer Will Trade At $40 On Improved Drug Pipeline – Pfizer Inc …

SummaryWith the stock trading at a P/E of 9, these shares are still cheap.
Pfizer is trading at a P/E that is almost 30 points below Merck (MRK), 13 points below Novartis (NVS) and 15 point below Sanofi (SNY).
At around $30 per share, investors that are looking for exposure in the health care industry and values 3.5% dividend yield should not […]

Broad and Novartis Keep Up with Big Data – Bio-IT World

By Matt Luchette May 15, 2014 | In the era of big data, drug developers are pushing for data
analysis to keep up with increased data acquisition. At this April’s Bio-IT
World Conference & Expo, Andrea DeSouza, from the Broad Institute, and Anne
Mai Wassermann, from Novartis, spoke on new technologies they hope will squeeze
meaning from researchers’ mounds of data.At the Broad […]